Last Updated: November 8, 2026

FINASTERIDE AND TADALAFIL Drug Patent Profile

Name: FINASTERIDE AND TADALAFIL Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Finasteride And Tadalafil patents expire, and when can generic versions of Finasteride And Tadalafil launch?

Finasteride And Tadalafil is a drug marketed by Novitium Pharma and Zydus Lifesciences and is included in two NDAs.

The generic ingredient in FINASTERIDE AND TADALAFIL is finasteride; tadalafil. There is one drug master file entry for this compound. Additional details are available on the finasteride; tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Finasteride And Tadalafil

A generic version of FINASTERIDE AND TADALAFIL was approved as finasteride; tadalafil by NOVITIUM PHARMA on March 19^th, 2025.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for FINASTERIDE AND TADALAFIL?
What are the global sales for FINASTERIDE AND TADALAFIL?
What is Average Wholesale Price for FINASTERIDE AND TADALAFIL?

Summary for FINASTERIDE AND TADALAFIL

US Patents:	0
Applicants:	2
NDAs:	2
Clinical Trials:	2
DailyMed Link:	FINASTERIDE AND TADALAFIL at DailyMed

Drug patent expirations by year for FINASTERIDE AND TADALAFIL

Recent Clinical Trials for FINASTERIDE AND TADALAFIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 2
Eli Lilly and Company	Phase 3

See all FINASTERIDE AND TADALAFIL clinical trials

US Patents and Regulatory Information for FINASTERIDE AND TADALAFIL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	FINASTERIDE AND TADALAFIL	finasteride; tadalafil	CAPSULE;ORAL	218499-001	Mar 19, 2025		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Lifesciences	FINASTERIDE AND TADALAFIL	finasteride; tadalafil	CAPSULE;ORAL	218232-001	Mar 15, 2024		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.